跳转至内容
Merck
CN

557368

Rotenone

≥98% (HPLC), solid, NADH-CoQ reductase inhibitor, Calbiochem

别名:

Rotenone

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C23H22O6
化学文摘社编号:
83-79-4
分子量:
394.42
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD09025614

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Rotenone, A mitochondrial toxin and a potent, reversible, and competitive inhibitor of complex I (NADH-CoQ reductase) of the respiratory chain.

SMILES string

O1[C@H]2[C@H](c5c(cc(c(c5)OC)OC)OC2)C(=O)c3c1c4c(cc3)O[C@H](C4)C(=C)C

InChI

1S/C23H22O6/c1-11(2)16-8-14-15(28-16)6-5-12-22(24)21-13-7-18(25-3)19(26-4)9-17(13)27-10-20(21)29-23(12)14/h5-7,9,16,20-21H,1,8,10H2,2-4H3/t16-,20-,21+/m1/s1

InChI key

JUVIOZPCNVVQFO-HBGVWJBISA-N

description

Merck USA index - 14 8271

assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

white to off-white

solubility

ethanol: 5 mg/mL, DMSO: 50 mg/mL, chloroform: 50 mg/mL

shipped in

ambient

storage temp.

10-30°C

Quality Level

100

正在寻找类似产品? 访问 产品对比指南

相关类别

General description

A mitochondrial toxin and a potent, reversible, and competitive inhibitor of complex I (NADH-CoQ reductase) of the respiratory chain. Also inhibits cellular proliferation in mouse liver.

Biochem/physiol Actions

Cell permeable: no
Primary Target
NADH-CoQ reductase
Product does not compete with ATP.
Reversible: yes

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot, flush with nitrogen, and store at -70°C. Stock solutions are stable for up to 1 month at -70°C.

Other Notes

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Kopustinskiene, D.M., et al. 2001. Eur. J. Pharmacol.428, 311.
Higgins, D.S., Jr. and Greenamyre, J.T. 1996. J. Neurosci. 16, 3807.
Cunningham, M.L., et al. 1995. Cancer Lett. 95, 93.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Toxic (F)

pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

signalword

Danger

Hazard Classifications

Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Aastha Garde et al.
STAR protocols, 3(2), 101429-101429 (2022-06-07)
Measuring ATP levels within the cytosol of living cells in animals is important to understand how cellular activities are energetically supported, but is challenging because of tissue complexity and ATP sensor limitations. In this protocol, we describe how to quantify
Andaleb Kholmukhamedov et al.
The Journal of biological chemistry, 298(9), 102336-102336 (2022-08-06)
Mitochondrial chelatable iron contributes to the severity of several injury processes, including ischemia/reperfusion, oxidative stress, and drug toxicity. However, methods to measure this species in living cells are lacking. To measure mitochondrial chelatable iron in living cells, here we synthesized
Localized glucose import, glycolytic processing, and mitochondria generate a focused ATP burst to power basement-membrane invasion.
Garde, et al.
Developmental Cell, 57, 732-749 (2023)
Tongling Liufu et al.
Frontiers in physiology, 14, 1164287-1164287 (2023-08-31)
Introduction: Mitochondrial disease is a spectrum of debilitating disorders caused by mutations in the mitochondrial DNA (mtDNA) or nuclear DNA that compromises the respiratory chain. Mitochondrial 3243A>G (m.3243 A>G) is the most common mutation showing great heterogeneity in phenotype. Previous
Jack Pengfei Tang et al.
Cancer immunology research, 10(12), 1433-1440 (2022-10-20)
A major complication of chimeric antigen receptor (CAR) T-cell therapy is immune effector cell-associated neurotoxicity syndrome (ICANS), which presents as aphasia, confusion, weakness, somnolence, seizures, and coma. This is similar to the neurologic manifestations of hypophosphatemia, which can result from
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持